558.63
price down icon0.79%   -4.47
pre-market  Pre-market:  558.91   0.28   +0.05%
loading
Regeneron Pharmaceuticals Inc stock is traded at $558.63, with a volume of 587.65K. It is down -0.79% in the last 24 hours and up +7.22% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$563.10
Open:
$563.53
24h Volume:
587.65K
Relative Volume:
0.47
Market Cap:
$59.30B
Revenue:
$14.09B
Net Income/Loss:
$4.50B
P/E Ratio:
14.22
EPS:
39.28
Net Cash Flow:
$2.96B
1W Performance:
+2.40%
1M Performance:
+7.22%
6M Performance:
-18.61%
1Y Performance:
-48.21%
1-Day Range:
Value
$558.54
$567.95
1-Week Range:
Value
$546.92
$577.73
52-Week Range:
Value
$476.49
$1,211.20

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Name
Regeneron Pharmaceuticals Inc
Name
Phone
(914) 847-7000
Name
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Employee
15,158
Name
Twitter
@regeneron
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-30-25 Downgrade Argus Buy → Hold
May-30-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-30-25 Downgrade Wells Fargo Overweight → Equal Weight
May-14-25 Upgrade Citigroup Neutral → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-05-25 Upgrade Leerink Partners Market Perform → Outperform
Jan-16-25 Downgrade UBS Buy → Neutral
Dec-10-24 Resumed BofA Securities Underperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Neutral
Sep-24-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-12-24 Initiated Bernstein Outperform
Jan-12-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Nov-03-23 Upgrade Raymond James Mkt Perform → Outperform
Aug-21-23 Upgrade Canaccord Genuity Hold → Buy
Aug-21-23 Reiterated Oppenheimer Perform
Jun-28-23 Downgrade Canaccord Genuity Buy → Hold
Mar-27-23 Upgrade SVB Securities Market Perform → Outperform
Mar-24-23 Upgrade Jefferies Hold → Buy
Mar-23-23 Upgrade Raymond James Underperform → Mkt Perform
Jan-30-23 Upgrade Cowen Market Perform → Outperform
Jan-20-23 Upgrade JP Morgan Neutral → Overweight
Oct-26-22 Downgrade Raymond James Mkt Perform → Underperform
Oct-17-22 Downgrade Evercore ISI Outperform → In-line
Sep-09-22 Upgrade Jefferies Underperform → Hold
Sep-09-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-25-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-06-22 Initiated Jefferies Underperform
May-23-22 Initiated SVB Leerink Outperform
Jan-05-22 Downgrade BofA Securities Neutral → Underperform
Jan-03-22 Upgrade Bernstein Mkt Perform → Outperform
Dec-15-21 Downgrade Bernstein Outperform → Mkt Perform
Dec-09-21 Resumed Wells Fargo Overweight
Dec-07-21 Resumed Cowen Market Perform
Dec-06-21 Initiated Goldman Buy
Nov-19-21 Resumed BMO Capital Markets Outperform
Nov-05-21 Downgrade The Benchmark Company Buy → Hold
Jun-29-21 Initiated H.C. Wainwright Buy
Jan-25-21 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-13-21 Upgrade The Benchmark Company Hold → Buy
Jan-08-21 Upgrade Citigroup Neutral → Buy
Oct-05-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Aug-20-20 Downgrade The Benchmark Company Buy → Hold
Jul-09-20 Upgrade SunTrust Hold → Buy
May-26-20 Upgrade Wells Fargo Equal Weight → Overweight
Apr-28-20 Downgrade Citigroup Buy → Neutral
Apr-17-20 Upgrade The Benchmark Company Hold → Buy
Apr-08-20 Initiated The Benchmark Company Hold
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Feb-26-20 Downgrade Robert W. Baird Outperform → Neutral
Feb-25-20 Upgrade Jefferies Hold → Buy
Feb-11-20 Upgrade Argus Hold → Buy
Dec-24-19 Initiated Raymond James Mkt Perform
Dec-16-19 Downgrade Evercore ISI Outperform → In-line
Dec-13-19 Upgrade Credit Suisse Neutral → Outperform
Nov-12-19 Initiated SunTrust Hold
Nov-07-19 Upgrade Citigroup Neutral → Buy
Oct-17-19 Resumed BofA/Merrill Neutral
Sep-23-19 Upgrade Guggenheim Neutral → Buy
View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

pulisher
03:33 AM

Phoenix Financial Ltd. Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

03:33 AM
pulisher
Jul 28, 2025

Pacer Advisors Inc. Buys 390,374 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

John G Ullman & Associates Inc. Acquires 3,115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

1,697 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Bellwether Advisors LLC - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

When is Regeneron Pharmaceuticals Inc. stock expected to show significant growthGet exclusive market insights for better trading - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

AE Wealth Management LLC Purchases 445 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

IFP Advisors Inc Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 28, 2025
pulisher
Jul 28, 2025

Canaccord Reiterates a Buy Rating on Regeneron Pharmaceuticals (REGN) - Insider Monkey

Jul 28, 2025
pulisher
Jul 28, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Boosted by Assetmark Inc. - MarketBeat

Jul 28, 2025
pulisher
Jul 27, 2025

Is Regeneron Pharmaceuticals Inc. stock overvalued or undervaluedInvest smarter with actionable market insights - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What catalysts could drive Regeneron Pharmaceuticals Inc. stock higher in 2025Achieve breakthrough investment performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the technical indicators suggesting about Regeneron Pharmaceuticals Inc.Build wealth with long-term growth strategies - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Regeneron Pharmaceuticals Inc. a growth stock or a value stockTrack top-performing stocks in real-time - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

ARK Investment Management LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

TD Asset Management Inc Sells 7,502 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

Nikko Asset Management Americas Inc. Has $15.31 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

Zurcher Kantonalbank Zurich Cantonalbank Sells 42,590 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

Mediolanum International Funds Ltd Has $21.17 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is Legato Capital Management LLC's 9th Largest Position - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

Rep. Robert Bresnahan, Jr. Buys Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

Pinnacle Associates Ltd. Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 27, 2025
pulisher
Jul 27, 2025

Regeneron Pharmaceuticals, Inc. (REGN) Acquires 23andMe Assets in $256M Deal - MSN

Jul 27, 2025
pulisher
Jul 26, 2025

Regeneron Pharmaceuticals Earnings Preview: What to Expect - MSN

Jul 26, 2025
pulisher
Jul 26, 2025

Regeneron Pharmaceuticals (REGN): Can Dupixent's Growth Offset Eylea Erosion and Drive Long-Term Earnings Resilience? - AInvest

Jul 26, 2025
pulisher
Jul 26, 2025

10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey

Jul 26, 2025
pulisher
Jul 25, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

Bank of America Securities Reiterated a Sell rating on Regeneron Pharmaceuticals (REGN), Lowered the PT - Insider Monkey

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Regeneron Pharmaceuticals Inc. stockExplosive capital gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Lifeworks Advisors LLC Buys 2,166 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance

Jul 25, 2025
pulisher
Jul 25, 2025

REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth? - Nasdaq

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Regeneron Pharmaceuticals Inc. stock priceTriple-digit return opportunities - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Regeneron Pharmaceuticals Earnings Preview: What To Expect - Barchart.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Regeneron Pharmaceuticals Inc. stock overhyped or has real potentialOutstanding risk-reward balance - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Polymyalgia Rheumatica Treatment Market Expands Due to Aging - openPR.com

Jul 25, 2025
pulisher
Jul 25, 2025

Regeneron Faces Growing Pains While Betting On Its Pipeline - Finimize

Jul 25, 2025
pulisher
Jul 25, 2025

Eosinophilic Esophagitis Treatment Market Boosted by Growth - openPR.com

Jul 25, 2025
pulisher
Jul 25, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Beacon Investment Advisory Services Inc. - MarketBeat

Jul 25, 2025
pulisher
Jul 24, 2025

Regeneron Pharmaceuticals Inc. Stock Analysis and ForecastExceptional stock performance - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Los Angeles Capital Management LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Regeneron Pharmaceuticals to Acquire 23andMe for $256M - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

BID aprueba préstamos por 1.200 million dlrs para Argentina - Yahoo Finanzas

Jul 24, 2025
pulisher
Jul 24, 2025

Private Advisor Group LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks

Jul 24, 2025
pulisher
Jul 24, 2025

Regeneron and Sanofi’s EoE Study with DUPIXENT®: Key Insights for Investors - The Globe and Mail

Jul 24, 2025
pulisher
Jul 24, 2025

September 5th Options Now Available For Regeneron Pharmaceuticals (REGN) - Nasdaq

Jul 24, 2025
pulisher
Jul 24, 2025

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Longleaf Partners Fund Increased its Holdings in Regeneron Pharmaceuticals (REGN) on a Dip - Insider Monkey

Jul 24, 2025

Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$324.79
price down icon 1.22%
$595.19
price up icon 0.54%
biotechnology ONC
$294.51
price up icon 1.04%
$112.79
price down icon 2.19%
$27.45
price down icon 4.26%
Cap:     |  Volume (24h):